Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TRILLION ENERGY’S GULUC-2 WELL TESTS 16.35 MMCF/DAY (click to learn more) Aton (V.AAN) Reports Diamond Drill Results, Including 1.38 g/t Au Eq & 8.20% Zn over 22.5m from Surface (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News EyePoint Pharmaceuticals Inc. EYPT

Healthcare Biotechnology
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:EYPT)

Fundamentals Snapshot (NDAQ:EYPT)

Current News (NDAQ:EYPT)

EyePoint Investor Alert

Newsfile 1 day ago

EyePoint Pharmaceuticals Completes Enrollment in Oversubscribed Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for Maintenance Treatment of Wet AMD

GlobeNewswire 2 days ago

EyePoint Shareholder Action Reminder

Newsfile 8 days ago

EyePoint Pharmaceuticals Announces Upcoming Data Presentations at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

GlobeNewswire 9 days ago

EyePoint Investor Alert

Newsfile March 12, 2023

EyePoint Investor Alert

Newsfile March 7, 2023

EyePoint Shareholder Notice

Newsfile March 5, 2023

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Developments

GlobeNewswire March 2, 2023

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

GlobeNewswire February 27, 2023
View More News ››

Opinion & Analysis (NDAQ:EYPT)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:EYPT)

Be the first to post on this bullboard.

Fineqia International Inc.

Fineqia International Inc.

Fineqia is a digital asset business that primarily builds and targets investments in early and growth stage technology ...
View More »